-
Tytuł:
-
Drug Policy in the Russian Federation.
-
Autorzy:
-
Holownia-Voloskova M; State Budgetary Institution 'Clinical Trials and Healthcare Technology Assessment Centre of Moscow Department of Health,' Moscow, Russia; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland. Electronic address: .
Vorobiev PA; Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia; I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Grinin M; State Budgetary Institution 'Clinical Trials and Healthcare Technology Assessment Centre of Moscow Department of Health,' Moscow, Russia.
Davydovskaya MV; State Budgetary Institution 'Clinical Trials and Healthcare Technology Assessment Centre of Moscow Department of Health,' Moscow, Russia.
Ermolaeva TN; State Budgetary Institution 'Clinical Trials and Healthcare Technology Assessment Centre of Moscow Department of Health,' Moscow, Russia.
Kokushkin KA; State Budgetary Institution 'Clinical Trials and Healthcare Technology Assessment Centre of Moscow Department of Health,' Moscow, Russia.
-
Źródło:
-
Value in health regional issues [Value Health Reg Issues] 2018 Sep; Vol. 16, pp. 106-111. Date of Electronic Publication: 2018 Oct 14.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: New York : Elsevier
-
MeSH Terms:
-
Drug Costs*
Economics, Pharmaceutical*
Public Policy*
Prescription Drugs/*economics
Reimbursement Mechanisms/*economics
Technology Assessment, Biomedical/*methods
Cost Control/economics ; Costs and Cost Analysis/economics ; Humans ; Prescription Drugs/supply & distribution ; Russia ; Technology Assessment, Biomedical/economics
-
Contributed Indexing:
-
Keywords: Russia; Russian Federation; drug policy; health policy
-
Substance Nomenclature:
-
0 (Prescription Drugs)
-
Entry Date(s):
-
Date Created: 20181018 Date Completed: 20190107 Latest Revision: 20190107
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.vhri.2018.09.001
-
PMID:
-
30327255
-
Objectives: To describe characteristics of the drug policy in Russia in terms of health technology assessment (HTA), registries of patients, pricing of drugs, cost-containment methods, and reimbursement of drugs.
Methods: The legal and regulatory frameworks and the literature were reviewed to analyze several aspects of Russian healthcare: the scheme of cooperation between its structures, its levels, drug provision, issues related to HTA, the reimbursement system, pricing of medicines, and cost-containment methods.
Results: The Russian drug policy has improved over the last few years: HTA has been developed, rules for the pricing of drugs and cost-containment methods have been established, and registries of patients have been created. The reimbursement system in Russia is different from the ones in Western Europe and consists of a few programs: reimbursement for specific categories of citizens, vital and essential drug list, list of 24 orphan diseases, list of 7 nosologies, and other programs, depending on region. Financing for drug provision in Russia is divided into 2 levels: federal and regional. There is still a lack of transparency and equality in healthcare as well as huge differences in access to healthcare, depending on region.
Conclusions: The healthcare system in Russia is complicated and needs improvement. Nowadays, changes are being made; for example, there are attempts to implement HTA at federal and regional levels.
(Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.)
